Technical Analysis for NUVL - Nuvalent, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 65.62 | -1.29% | -0.86 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Support | Bullish | -1.29% | |
| Doji - Bullish? | Reversal | -1.29% | |
| Outside Day | Range Expansion | -1.29% | |
| 200 DMA Support | Bullish | -0.64% | |
| NR7 | Range Contraction | -0.64% | |
| Gapped Down | Weakness | -0.64% | |
| MACD Bearish Signal Line Cross | Bearish | -2.18% |
| Alert | Time |
|---|---|
| Fell Below 200 DMA | 1 day ago |
| 200 DMA Support | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Nuvalent, Inc. Description
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organic Compounds Chemical Compounds Tyrosine Kinase Receptors Preclinical Stage Biopharmaceutical Anaplastic Lymphoma Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 89.39 |
| 52 Week Low | 38.78 |
| Average Volume | 470,872 |
| 200-Day Moving Average | 65.95 |
| 50-Day Moving Average | 69.35 |
| 20-Day Moving Average | 68.42 |
| 10-Day Moving Average | 68.12 |
| Average True Range | 2.77 |
| RSI (14) | 40.83 |
| ADX | 15.25 |
| +DI | 20.62 |
| -DI | 23.64 |
| Chandelier Exit (Long, 3 ATRs) | 66.49 |
| Chandelier Exit (Short, 3 ATRs) | 72.48 |
| Upper Bollinger Bands | 72.59 |
| Lower Bollinger Band | 64.25 |
| Percent B (%b) | 0.16 |
| BandWidth | 12.20 |
| MACD Line | -0.83 |
| MACD Signal Line | -0.54 |
| MACD Histogram | -0.2873 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 69.76 | ||||
| Resistance 3 (R3) | 69.77 | 68.39 | 69.07 | ||
| Resistance 2 (R2) | 68.39 | 67.34 | 68.39 | 68.84 | |
| Resistance 1 (R1) | 67.01 | 66.69 | 66.32 | 67.00 | 68.61 |
| Pivot Point | 65.63 | 65.63 | 65.29 | 65.63 | 65.63 |
| Support 1 (S1) | 64.25 | 64.58 | 63.56 | 64.24 | 62.63 |
| Support 2 (S2) | 62.87 | 63.93 | 62.87 | 62.40 | |
| Support 3 (S3) | 61.49 | 62.87 | 62.17 | ||
| Support 4 (S4) | 61.48 |
